Peptide half-life is the time for a specified measured amount or concentration to fall by half during the phase being described. It does not automatically tell you how long an effect lasts, how often a medicine is used or how long a laboratory solution remains stable.
If your question is about half-life in PRRT, the distinction is between radioactive decay, biological clearance and their combined effect. The short explanation below separates those meanings; the dedicated PRRT half-life guide covers the radiopharmaceutical context in more detail.
What does half-life mean in PRRT?
In peptide receptor radionuclide therapy, physical half-life describes radioactive decay. Biological half-life describes removal from the body or a specified compartment, considered separately from decay. Effective half-life combines decay and biological removal for the compartment and model being studied.
The IAEA radiopharmaceutical guidance, section 6.1.2, explains how physical decay and biological clearance contribute to a time–activity curve. A value for the radionuclide alone is therefore not automatically the same as the effective half-life measured in an organ. Neither number, on its own, states how long a clinical response lasts.
Half-life vs duration of action: four different questions
Scroll horizontally to read all columns.
| Term | What it describes | What it does not establish |
|---|---|---|
| Elimination half-life | A decline in the measured amount or concentration during a specified phase. | The exact beginning or end of every effect. |
| Duration of action | How long a defined effect persists under the measurement used. | The chemical stability of a stored solution. |
| Formulation release | How material becomes available from a preparation over time. | The molecule's clearance after release. |
| Shelf life or solution stability | How a product or sample changes under specified storage conditions. | Its elimination from a biological system. |
The practical question is: what is falling by half? A parent peptide in plasma, radioactivity in a tissue and an analytical signal from a stored sample are different quantities. The word “half-life” does not make those measurements interchangeable.
A simple peptide half-life calculation
For a single first-order decline, with absorption complete and no further input, the fraction remaining after a given time is (1/2)^(elapsed time ÷ half-life). Each complete half-life halves the amount remaining; it does not remove the same absolute amount each time.
Scroll horizontally to read all columns.
| Half-lives elapsed | Amount remaining from 100 arbitrary units | Percentage remaining |
|---|---|---|
| 0 | 100 | 100% |
| 1 | 50 | 50% |
| 2 | 25 | 25% |
| 3 | 12.5 | 12.5% |
| 4 | 6.25 | 6.25% |
| 5 | 3.125 | About 3.1% |
After five half-lives, this model leaves about 3.1% of the starting amount. It does not predict zero. More importantly, the table is arithmetic under stated assumptions: it is not a washout period, a preparation protocol or an instruction for using a medicine. Continued absorption, repeated input or several distribution phases can make a real concentration–time profile more complex.
Why the effect can last for a different time
The U.S. Wegovy prescribing information, section 12.3, reports a semaglutide elimination half-life of approximately one week. That is a pharmacokinetic measurement. It does not mean that weight, appetite or every other outcome resets at a seven-day boundary.
Clinical outcomes require their own measurements and follow-up. The semaglutide plateau guide, for example, examines weight trajectories over months and years. A trial's weight curve answers a different question from a plasma concentration curve.
Formulation matters too. The Sandostatin LAR label distinguishes octreotide pharmacokinetics from the release profile of its depot formulation. A slow-release preparation should not be described simply by copying an immediate-release half-life into a comparison chart. The octreotide and lanreotide comparison follows that formulation-specific distinction.
Why two published half-lives may differ
Before deciding that two reports disagree, check whether they measured the same molecule, formulation, sample and phase. A terminal estimate after the initial distribution phase may answer a different question from a short early sampling window. An assay for intact peptide may also differ from a measurement that includes related material.
Population and route belong beside the number. An estimate in a defined clinical study does not automatically establish a value for a different research material or experimental system. A useful comparison preserves those details rather than selecting the longer or shorter value without explanation.
A traceable statement reads: “In this study population, this formulation and route produced this measured half-life for this analyte under this model.” That sentence is more informative than a molecule name followed by a number.
Can half-life tell you a solution's shelf life?
A biological elimination estimate cannot supply a storage expiry date. Temperature, pH, light, container interactions and the analytical definition of stability belong to a separate experiment. A sample could retain one analytical attribute while another changes; “stable” needs a measurement and an acceptance criterion.
Use the peptide stability and degradation guide for that question. For any half-life claim, keep five details in view: the measured quantity, formulation, sample or population, sampling interval and model assumptions. Those details determine whether a number is relevant to the question you actually want to answer.
